|1.||Schulz, Richard: 2 articles (10/2015 - 11/2010)|
|2.||Saiki, Ikuo: 2 articles (05/2003 - 02/2002)|
|3.||Sawada, Shigeaki: 2 articles (05/2003 - 02/2002)|
|4.||Tsukada, Kazuhiro: 2 articles (05/2003 - 02/2002)|
|5.||Miki, Toyokazu: 2 articles (03/2003 - 10/2002)|
|6.||Yamamoto, Akihiko: 2 articles (03/2003 - 10/2002)|
|7.||Yano, Seiji: 2 articles (03/2003 - 10/2002)|
|8.||Shiraga, Minoru: 2 articles (03/2003 - 10/2002)|
|9.||Goto, Hisatsugu: 2 articles (03/2003 - 10/2002)|
|10.||Sone, Saburo: 2 articles (03/2003 - 10/2002)|
05/01/2006 - "Hepatic ischemia/reperfusion injury is prevented by a novel matrix metalloproteinase inhibitor, ONO-4817."
05/01/2006 - "Hepatic ischemia/reperfusion injury was improved by a novel MMP inhibitor, ONO-4817, not only by inhibition of gelatinolytic activity but also by a decrease in release of inflammatory cytokines."
05/01/2006 - "ONO-4817 prevented ischemia/reperfusion injury to the hepatocytes as shown by significant reductions of serum alanine aminotransferase and less severe histologic changes. "
02/01/2006 - "Our data show that ONO-4817 prevented neutrophil migration into the interstitial space and alveolus in the lungs, and reduced the production of oxygen free radicals, suggesting that this is an important mechanism in reperfusion injury."
|3.||Neoplasm Metastasis (Metastasis)
05/01/2003 - "Moreover, ONO-4817 significantly inhibited lung metastasis. "
03/01/2003 - "Monotherapy with ONO-4817 or DOC inhibited formation of lung metastasis by PC14PE6 and H226 cells. "
11/01/2001 - "In conclusion, ONO-4817 effectively inhibited lung metastasis of Renca cells through its anti-invasive and anti-angiogenic properties. "
05/01/2003 - "The MMP inhibitor, ONO-4817, is a candidate for adjunctive therapy of cervical lymph node metastasis in tongue carcinoma."
05/01/2003 - "We investigated the inhibitory effect of ONO-4817 on cervical lymph node metastasis of tongue carcinoma. "
03/01/2003 - "In addition, combined use of ONO-4817 with DOC significantly suppressed the tumor burden of H226 and PC14PE6 cells in the lung and prolonged the survival of PC14PE6-bearing mice compared to ONO-4817 or DOC alone. "
11/01/2002 - "The periods between the occurrence of the first and second tumors, and the second and third ones were significantly increased in the mice treated with ONO-4817 compared to the mice not given ONO-4817 treatment. "
11/01/2002 - "Any second mammary tumor developing in the other mammary fat pad was also removed, and the mice were continuously fed the chow containing ONO-4817. "
11/01/2002 - "The first palpable tumor was removed, and the mice were thereafter fed chow containing ONO-4817. "
11/01/2001 - "We also found that oral administration of ONO-4817 significantly inhibited the angiogenic response (number of vessels oriented towards the tumor mass) and the growth of tumors inoculated i.d. "
11/01/2002 - "The degree of pathological progression of adenomyosis was less in the uteri exposed to ONO-4817 than in the uteri not exposed to the inhibitor."
11/01/2002 - "Second, to test ONO-4817 suppression of the progression of the invasion of uterine adenomyotic tissue, mice with experimentally-induced adenomyosis were treated with ONO-4817 for 4 weeks. "
05/01/2001 - "These results indicate that ONO-4817 may be an effective inhibitor of the development of adenomyosis."
05/01/2001 - "The degree of pathological progression of adenomyosis was graded from 1 to 5 in increments of 1. The degree of the progression of the lesion was less in the uteri exposed to ONO-4817 (2.71 +/- 0.93) than in the uteri not exposed to the inhibitor (4.33 +/- 0.75). "
05/01/2001 - "Mice treated with 0.3% or 1.0% ONO-4817 showed a significantly lower incidence of the development of adenomyosis than vehicle-treated mice. "
|10.||Alanine Transaminase (SGPT)